Papers
7
Total Citations
80
H-Index
4
About
Michael Repka is a radiation oncologist whose research centers on stereotactic body radiation therapy (SBRT), with particular expertise in genitourinary and thoracic malignancies. His work has meaningfully advanced the clinical application of SBRT in challenging patient populations and treatment scenarios where conventional approaches fall short. Repka's most impactful contribution examines five-fraction SBRT for ultra-central non-small cell lung cancer recurrences following prior high-dose radiation—a notoriously difficult clinical problem—garnering 32 citations and helping establish SBRT as a viable salvage strategy. In prostate cancer, his research spans a remarkably broad range of clinical questions: managing acute urinary morbidity through alpha-adrenergic antagonists and urethral dose reduction (24 citations), treating patients with inflammatory bowel disease, safely placing fiducial markers in anticoagulated patients, and delivering SBRT to ultra-large prostates exceeding 100cc. Notably, his work on salvage SBRT following cryoablation failure addresses a genuinely underexplored area of prostate cancer retreatment. Across his portfolio, Repka consistently pushes SBRT into populations historically considered high-risk or ineligible for radiation, demonstrating both technical innovation and a commitment to expanding treatment access for complex patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7